LPA and atherosclerosis: A phase 3 CV outcomes study is ongoing, entitled “A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a)-ACCLAIM-Lp(a)” (NCT06292013), which will involve approximately 12,500 patients with ASCVD (aged >18 years with an event or revascularization) or at risk high risk of ASCVD (aged >55 years with atherosclerotic disease and without a clinical event, revascularization, FH, or presence of multiple risk factors) and with a baseline Lp(a) level ≥175 nmol/L [57].